On October 2, 2024, Zydus Lifesciences Limited (including its subsidiaries/affiliates, collectively called “Zydus”) received tentative approval from the USFDA to produce Enzalutamide Tablets in 40 mg and 80 mg doses (a generic version of Xtandi® Tablets). These tablets are used to treat patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. The tablets will …